HB 467 Summary

• Amends controlled substance schedules by reclassifying certain synthetic cannabinoids and designer drugs (methylone, MDPV, mephedrone, and methcathinone derivatives) from Schedule I hallucinogens to Schedule I stimulants.

• Expands enforcement powers of health care licensing boards (medical, dental, nursing, pharmacy) by allowing boards to conduct investigations, inspections, and issue subpoenas with specific procedures for subpoena service and patient record disclosure.

• Establishes regulatory requirements for pain management clinics operated by physicians, including ownership restrictions, criminal background checks for employees and owners, and compliance with state medical board rules on clinic operations.

• Imposes limits on prescriber-furnished controlled substances: maximum 2,500 dosage units per 30-day period and no more than 72-hour supply per patient, with exceptions for methadone, buprenorphine, and clinical research.

• Creates a quality intervention program within the medical board to provide remedial education for physicians with clinical or communication skill deficiencies as an alternative to formal disciplinary action in appropriate cases.